Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Pfizer
|
| gptkbp:acquisitionYear |
2023
|
| gptkbp:focus |
molecular diagnostics
|
| gptkbp:founded |
2013
|
| gptkbp:founder |
Chun-Hao Huang
Debkishore Mitra John Waldeisen |
| gptkbp:headquartersLocation |
gptkb:Emeryville,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Lucira Health
|
| gptkbp:industry |
gptkb:biotechnology
medical devices |
| gptkbp:notableAchievement |
First FDA-authorized at-home COVID-19 molecular test
|
| gptkbp:notableEvent |
FDA emergency use authorization for COVID-19 test in 2020
|
| gptkbp:notableProduct |
COVID-19 at-home test kit
Influenza A/B at-home test kit |
| gptkbp:publiclyTraded |
yes
|
| gptkbp:status |
acquired
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
LHDX
|
| gptkbp:website |
https://www.lucirahealth.com/
|
| gptkbp:bfsParent |
gptkb:Stanley_Lapidus
|
| gptkbp:bfsLayer |
7
|